HOME > ACADEMIA
ACADEMIA
- As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria
June 4, 2021
- NCC, 5 Other Institutions Forge Genome Cohort of 366,000 People
May 28, 2021
- Hematologist Sees No Swelling Costs from 2 New CAR-T Contenders in Japan; Will Competition Drive Down Prices?
May 28, 2021
- New AMR Prevention Technology Could Contribute to Antiviral Development; Application to COVID-19 Meds Expected: Professor
May 17, 2021
- Olumiant Expected to Shorten Time to Recovery from COVID-19: Infection Expert
May 12, 2021
- No. of New Lung Cancer Patients Fell 6.6% in 2020 amid COVID-19: Survey
May 11, 2021
- Survival Rate Declines for Some Cancers Even after 5 Years: NCC
April 28, 2021
- New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
- Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
March 15, 2021
- COVID-19 Vaccination Should Be Avoided in Patients with Severe Hypersensitivity to PEG: Allergy Society
March 3, 2021
- Thorough Medication Guidance through Regional Collaboration Important for Rybelsus: Professor
February 22, 2021
- NCGM to Initiate Clinical Study of Convalescent Plasma Therapy for COVID-19 as Early as February
January 28, 2021
- Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor
January 22, 2021
- Antitussive Cloperastine Strongly Attacks Cisplatin-Resistant Cancer Cells: Research Group
January 22, 2021
- Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
- NCGM, Fujita Univ. to Join NIH’s Immunoglobulin Trial for COVID-19
December 24, 2020
- Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
- 4 Scientific Societies Call for COVID-19 Vaccine Recipient Registry
November 30, 2020
- Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
- 5-Year Cancer Survival Rate at 68.6%, Largely Unchanged: NCC
November 24, 2020
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…